NasdaqCM · Biotechnology

Exicure (XCUR)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered

Ratings unavailable

$1.15-0.15 (-11.5%)Latest market snapshot · Yahoo Finance

Market cap$7.5M

Cash$1.7M

Quarterly burn$1.1M

Pipeline assets1

Short float3.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

Analyst expectations are available belowTargets are estimates—not guarantees—and can change after company updates.

—Average target

Wall Street consensus

Not availableCoverage varies by company

—ratings

Buy 0Hold 0Sell 0

Price-target range

—

Low —High —

CurrentAverage

Bear case——

Base case——

Bull case——

Analyst coverage—published opinions

Bullish share—buy recommendations

Target spread—low-to-high dispersion

Consensus score—1.0 is strongest

Recommendation mix

Current rating breakdown

0 tracked ratings

No detailed rating distribution is available.

Company profile

About Exicure

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.